09:37 AM EDT, 10/20/2025 (MT Newswires) -- Merck ( MRK ) said Monday that new long-term data from a phase 3 trial of its cancer drug Keytruda showed sustained survival benefits in patients with earlier or advanced stages of non-small cell lung cancer.

The drugmaker said that five-year follow-up data on Keytruda continued to show a clinically meaningful improvement in overall survival and event free survival in patients with stage II, IIIA or IIIB non-small cell lung cancer.

Merck ( MRK ) also provided eight and 10-year study findings, which showed that Keytruda monotherapy continued to improve survival in certain patients with locally advanced or metastatic non-small cell lung cancer.

Price: 85.25, Change: +0.46, Percent Change: +0.54